Jeena Sikho Lifecare Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Revenue surged 74% YoY, driven by private patients: Private Panchakarma and medicine sales both grew 74% YoY, while government business was deliberately cut from ~25% to 8% to manage receivables.
• Occupancy on mature beds hit 80%, proving the model: Overall occupancy rose to 57% across 2,180 beds, but the original 1,600 beds ran at 80%, showing new beds drag the average while the core unit is highly profitable.
• OTC launch is the big bet, targeting ₹500 cr in 1.5–2 years: The first product sold out in 4 days; management targets 10 lakh pieces per month and a 20% PAT margin, with 15 products in the pipeline.
• Margins spiked to ~29–30% PAT, but management calls it a "lottery": The surge came from a rate hike, operating leverage, and reduced ad spend; the stated sustainable target remains 20–25%.
• What to watch next quarter: OTC distribution build-out in Gujarat and Maharashtra, the pace of bed additions toward the 2,850–3,000 March target, and whether the PAT margin normalizes toward the 20–25% band.

The OTC Pivot: Product Launch, Distribution & Ambition

• First product launched and sold out: The PET Liver Shuddhi Kit launched on 22nd August in Lucknow, got 21 orders in the first hour, and sold out completely within 4 days; more goods have since been purchased.
• Distribution network being built now: A super distributor network is forming, with the first in Lucknow and 16 parties finalized; Gujarat super distributor gave an advance cheque of ₹11,01,000. Super distributors will be made in September–October, with Gujarat and Maharashtra launches in November–December.
• Contract manufacturing secured in four states: Agreements are in place for localized production in Punjab, UP, Maharashtra, and Gujarat, with regional language packaging; a large owned manufacturing unit will be bought next year when production reaches 10–20 lakh pieces per month.
• Pipeline of 15 products, differentiated by clinical trials: 15 products are planned over 1–1.5 years, including medicines for BP, sugar, kidney, liver, depression, anxiety, sexual wellness, and blood purifier; 12 clinical trials are visible on the ICMR CTRI website, with 3 completed.
• Revenue ambition is ₹500 cr at 20% PAT margin: Management frames this as 0.025% of the ₹2 lakh cr pharma market; selling 10 lakh kits per month would yield ~₹55 cr monthly turnover, or ~₹600 cr annually.
• OTC is designed to feed hospital admissions: Product boxes will include hospital and clinic details; management expects 10 lakh monthly OTC users will drive hospital footfall, filling empty beds.

Manish Grover: "Sir, the products that I am bringing in the world no one has even thought about it. Sir, I have told you that everyone is thinking to sell products and earn money, my product is to sell products and earn blessings, to sell products and make India the world guru to sell products and make Ayurveda the number one this is my thought money will come by itself."

Hospital & Bed Expansion: The College Tie-Up Model

• Beds added without capex via Ayurvedic college tie-ups: The company reached 2,570 beds in three months by partnering with colleges, avoiding owned infrastructure spend; Mohali hospital is operational, a 150-bed Vrindavan hospital starts next month, and Aurangabad follows in ~3 months.
• Target is 2,850–3,000 beds by March, 7,000–10,000 in 3–5 years: The near-term target implies adding roughly 300–450 more beds this fiscal year; the long-term ambition targets ~1,000 beds per year.
• Mature beds are the profit engine: The original 1,600 beds now run at 80% occupancy, while overall 2,180 beds sit at 57% because new beds are added every 2–3 months and take time to fill; management will disclose a bifurcated occupancy split in future presentations.
• FOCO franchise model launching in 15–20 days: A Franchisee Owned, Company Operated model will be offered, where the franchisee invests and the company runs operations; the first three franchise locations (Mohaliwala, then Aurangabad) will be proven successful before expanding further.
• Own hospitals opened in South India: Company-owned hospitals are now operational in Chennai, Bangalore, Hyderabad, and Assam; 16 hospitals have already approached the company with partnership offers.

Manish Grover: "This will be a win-win situation for both."

Patient Volumes & Demographics

• Patient admissions have compounded rapidly: Total admitted patients grew from 5,700 (FY23) to 13,000 (FY24) to 24,500 (FY25); Q1 FY26 alone saw 8,600 admissions. OPD patients grew from 1,57,000 (FY23) to 2,52,000 (FY24) to 3,37,000 (FY25), with Q1 FY26 at 1,25,000.
• Wellness patients are a growing, distinct cohort: Patients without disease (wellness seekers) have risen from 2–3% to 10–12% of footfall; chronic patients with BP, diabetes, and thyroid conditions remain the majority. Patients aged 25–30 are only 2–4% of the total.
• Patient stay extended operationally: Average stay was increased from 8–9 days to 12–14 days in some hospitals through operational changes, contributing to revenue without raising the bed ticket price.
• Seasonal dips are structural, not alarming: Patient numbers decrease in November–January (North Indian cold) and during Diwali when patients go home for 5–7 days; unlike allopathy hospitals, patients can leave freely as no IVs or injections are administered.

Revenue Mix & Government Business Retreat

• Private business now 92% of revenue, up from ~75%: Government business was deliberately reduced from ~25% to 8% in Q1 because of payment delays of 4–6 months and the CAPF portal not being ready; management has formally told the government it will not expand government work until payments are corrected.
• Government receivables stand at ~₹70 cr, with ~₹25 cr received: Management expects another ₹15–20 cr in the next 3 months; the Bihar and Maharashtra governments have started passing employee bills under Ayurveda, which may improve the payment cycle.
• Medicine sales grew from ₹63 cr to ₹80 cr QoQ: Private Panchakarma rose from ₹47 cr to ₹78 cr, while government Panchakarma was cut from ₹28 cr to ₹15 cr; the deliberate shift toward private business is the core revenue story this quarter.
• Franchise clinics are immaterial to revenue: The old franchise model was weak and was rationalized from 60 to 36 clinics over three years; these 36 clinics contribute only ₹3 cr of total revenue, while hospitals, daycare centers, and government business contribute ₹57 cr.

Manish Grover: "I have clearly put a letter to the government that if you correct your payment, then we will work for the government or else we will not do it."

Margins: The "Lottery" Quarter & Sustainable Targets

• PAT margin spiked to ~29–30%, but management calls it a one-off: The surge came from a 15% rate increase effective April 1, rising bed occupancy, operating leverage on a ~₹30 cr/month fixed cost base, and a 3% reduction in marketing spend versus the prior quarter. Management explicitly labels the elevated margin a "lottery" and insists the sustainable target is 20–25%.
• Operating expenses fell despite adding beds: Total opex dropped from ₹79.43 cr to ₹77.14 cr QoQ, achieved by renegotiating supplier contracts (bedsheets, towels, oils) with volume commitments.
• Direct expense ratios expected to stay constant: Medicine costs are maintained at 15% and consumption at 9% of revenue; management expects these ratios to hold, implying profitability will increase if revenue grows while costs remain fixed.
• Free treatment is a deliberate margin investment: 9–10% of admitted patients (the impoverished) receive free treatment; management views these patients as word-of-mouth generators and "blessings" that reduce the need for advertising spend.

Manish Grover: "So, this margin -- we consider it as a lottery."

People, Governance & International Steps

• Doctor headcount has more than doubled in two years: Doctors increased from 230 (2023) to 532 currently; total employees grew from 2,400 to 4,000 over the same period.
• Main board migration and auditor upgrade completed: The company migrated to the NSE and BSE main board on 11th August; Grant Thornton (Walker Chandiok) has been appointed as statutory auditor from Q2 onwards, replacing the current statutory auditor.
• CEO search continues, COO promoted internally: Manish Grover is acting as CEO while the search for a "dangerous person with energy like me" continues; a COO has been promoted internally and the update will be filed with the exchange soon.
• International clinics opened in Dubai and Abu Dhabi: Two clinics are operational, with final approval expected in 2–4 days; four more are planned. The Nepal hospital is operational and generated a profit of ~₹10 lakhs in 3 months.
• ESOP costs are minor and being finalized: Historical ESOP expense was ₹50–60 lakhs; new ESOPs are being finalized and the Board will decide on vesting; existing ESOP expense will be bifurcated over the next 5 years with minor impact.

Manish Grover: "I need a dangerous person with energy like me. The one who sleeps at night, keeps waking up all day like me, keeps running all day. One day Mumbai, one day Lucknow."

Guidance & Commitments

Key Metrics